HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Smartphone app Detects Neonatal Jaundice in Minutes

By HospiMedica International staff writers
Posted on 16 Sep 2014
Image: The BiliCam app reporting that bilirubin levels are normal (Photo courtesy of the University of Washington).
Image: The BiliCam app reporting that bilirubin levels are normal (Photo courtesy of the University of Washington).
A new smartphone app could serve as a screening tool to ascertain whether a baby needs a blood test to determine bilirubin levels.

The BiliCam app, developed by researchers at the University of Washington (UW, Seattle, USA), evaluates a newborns skin tone relative to an included color calibration card (to account for different lighting conditions and skin tones). After capturing the data using the smartphone camera, the photo is sent to the cloud, where it is analyzed by machine-learning algorithms. The report on the newborn’s estimated bilirubin levels is delivered within minutes to doctors and parents.

The UW researchers ran a clinical study with 100 newborns and their families at UW Medical Center, comparing the BiliCam to a standard blood test; the app performed as well as or better than the current screening tool. The researchers plan to test BiliCam on up to 1,000 additional newborns, especially those with darker skin pigments; the algorithms will then be robust enough to account for all ethnicities and skin colors. Though it would not replace a blood test, BiliCam could also become a useful tool in developing countries where jaundice accounts for many newborn deaths.

“Virtually every baby gets jaundiced, and we’re sending them home from the hospital even before bilirubin levels reach their peak,” said professor of pediatrics James Taylor, MD, medical director of the newborn nursery at UW Medical Center. “This smartphone test is really for babies in the first few days after they go home. A parent or health care provider can get an accurate picture of bilirubin to bridge the gap after leaving the hospital.”

“BiliCam would be a significantly cheaper and more accessible option than the existing reliable screening methods,” added Lilian de Greef, MSc, a UW doctoral student in computer science and engineering. “Lowering the access barrier to medical applications can have profound effects on patients, their caregivers, and their doctors, especially for something as prevalent as newborn jaundice.”

Neonatal jaundice is a yellowing of the skin and other tissues of a newborn infant as a result of a bilirubin level of more than 5 mg/dL. Jaundiced newborns have an apparent icteric sclera and yellowing of the face, extending down onto the chest. The condition affects 50%–60% of all babies in the first week of life. Prolonged hyperbilirubinemia can result into chronic bilirubin encephalopathy (kernicterus). Treatment includes phototherapy using a blue light at a wavelength of 420–448 nm, which oxidizes bilirubin to biliverdin.

Related Links:

University of Washington


Gold Member
12-Channel ECG
CM1200B
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
High Pressure Balloon Catheter
UroMax Ultra
New
High-Precision QA Tool
DEXA Phantom

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more